# Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Source: https://onco.cc/trials/nct05691491/  
OnCo record `nct05691491` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of temozolomide in colorectal cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness is a phase 1/2, interventional study registered as NCT05691491 by National Cancer Institute (NCI), with a registry enrolment figure of 42 participants, started 2023-09-28 and due to reach its primary completion in 2027-03-01. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Temozolomide; Tuvusertib. Conditions listed: Advanced Malignant Solid Neoplasm; Advanced Microsatellite Stable Colorectal Carcinoma; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm; Metastatic Microsatellite Stable Colorectal Carcinoma; Stage III Colorectal Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8. Primary outcome: Dose limiting toxicity and the maximum tolerated dose. Colorectal eligibility wording from the registry: "Patients with MGMT promoter hypermethylated colorectal cancer must be mismatch repair proficient / microsatellite stable". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05691491
- Phase: 1/2
- Setting: A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT05691491: https://clinicaltrials.gov/study/NCT05691491

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Temozolomide](https://onco.cc/drugs/temozolomide/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05691491.json